Pacira Pharma (PCRX) Tops Q4 EPS by 12c, Revenue Beats; Offers FY20 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:01 AM EST Full-year 2019 revenue increases 25 percent to $421 million versus 2018
Total 2020 revenue guidance of between $485 million and $500 million
Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth
Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20... More
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:00 AM ESTFull-year 2019 revenue increases 25 percent to $421 million versus 2018 Total 2020 revenue guidance of between $485 million and $500 million Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20 percent growth, said Dave... More
